BioPorto A/S

CPSE:BIOPOR Stock Report

Market Cap: DKK 697.8m

BioPorto Valuation

Is BIOPOR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BIOPOR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate BIOPOR's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate BIOPOR's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BIOPOR?

Key metric: As BIOPOR is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for BIOPOR. This is calculated by dividing BIOPOR's market cap by their current revenue.
What is BIOPOR's PS Ratio?
PS Ratio20x
SalesDKK 34.91m
Market CapDKK 697.76m

Price to Sales Ratio vs Peers

How does BIOPOR's PS Ratio compare to its peers?

The above table shows the PS ratio for BIOPOR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average14.4x
BAVA Bavarian Nordic
2.6x2.4%DKK 15.6b
GMAB Genmab
4.7x14.4%DKK 94.2b
ORY Oryzon Genomics
6.5x61.7%€98.1m
A084990 Helixmith
43.7xn/a₩138.6b
BIOPOR BioPorto
20x31.7%DKK 697.8m

Price-To-Sales vs Peers: BIOPOR is expensive based on its Price-To-Sales Ratio (20x) compared to the peer average (14.4x).

Price to Sales Ratio vs Industry

How does BIOPOR's PS Ratio compare vs other companies in the European Biotechs Industry?

38 CompaniesPrice / SalesEstimated GrowthMarket Cap
BIOPOR 20.0xIndustry Avg. 8.1xNo. of Companies38PS0816243240+
38 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: BIOPOR is expensive based on its Price-To-Sales Ratio (20x) compared to the European Biotechs industry average (7.9x).

Price to Sales Ratio vs Fair Ratio

What is BIOPOR's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BIOPOR PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio20x
Fair PS Ratio6.1x

Price-To-Sales vs Fair Ratio: BIOPOR is expensive based on its Price-To-Sales Ratio (20x) compared to the estimated Fair Price-To-Sales Ratio (6.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies